EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Advances in high‐throughput mass spectrometry in drug discovery

Maria Emilia Dueñas iD, Rachel E Peltier-Heap iD, Melanie Leveridge, Roland S Annan, Frank H Büttner, Matthias Trost iD

EMBO Molecular Medicine · 11.01.2023 · 15 (1)

DOI: 10.15252/emmm.202114850 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift EMBO Molecular Medicine, online erschienen am 14.12.2022. Verfasst von Maria Emilia Dueñas und 5 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory for Biomedical Mass Spectrometry, Biosciences Institute, Newcastle University, Newcastle-upon-Tyne, UK. Hauptthemen laut MEDLINE: Drug Discovery, High-Throughput Screening Assays. Die Arbeit wurde bisher 133-mal zitiert (Crossref) und nennt 121 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: H2020 European Research Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

High‐throughput (HT) screening drug discovery, during which thousands or millions of compounds are screened, remains the key methodology for identifying active chemical matter in early drug discovery pipelines. Recent technological developments in mass spectrometry (MS) and automation have revolutionized the application of MS for use in HT screens. These methods allow the targeting of unlabelled biomolecules in HT assays, thereby expanding the breadth of targets for which HT assays can be developed compared to traditional approaches. Moreover, these label‐free MS assays are often cheaper, faster, and more physiologically relevant than competing assay technologies. In this review, we will describe current MS techniques used in drug discovery and explain their advantages and disadvantages. We will highlight the power of mass spectrometry in label‐free in vitro assays, and its application for setting up multiplexed cellular phenotypic assays, providing an exciting new tool for screening compounds in cell lines, and even primary cells. Finally, we will give an outlook on how technological advances will increase the future use and the capabilities of mass spectrometry in drug discovery.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drug DiscoveryHigh-Throughput Screening AssaysMass Spectrometry

Stichwörter der Autor:innen

MALDI-TOFaffinity selectiondrug discoveryhigh-throughput screeningmass spectrometry

Autor:innen und Institutionen

  • Laboratory for Biomedical Mass Spectrometry, Biosciences Institute, Newcastle University, Newcastle-upon-Tyne, UK.
  • Discovery Analytical, Screening Profiling and Mechanistic Biology, GSK R&D, Stevenage, UK.
  • Drug Discovery Sciences, High Throughput Biology, Boehringer Ingelheim Pharma GmbH&CoKG, Biberach, Germany.

ORCID-Profile: Maria Emilia Dueñas, Rachel E Peltier-Heap, Matthias Trost

Förderung

  • H2020 European Research Council

Zitieren

APA

Dueñas, M. E., Peltier-Heap, R. E., Leveridge, M., Annan, R. S., Büttner, F. H., & Trost, M. (2023). Advances in high‐throughput mass spectrometry in drug discovery. EMBO Molecular Medicine, 15(1). https://doi.org/10.15252/emmm.202114850

Vancouver

Dueñas ME, Peltier-Heap RE, Leveridge M, Annan RS, Büttner FH, Trost M. Advances in high‐throughput mass spectrometry in drug discovery. EMBO Molecular Medicine. 2023;15(1). doi:10.15252/emmm.202114850

BibTeX
@article{Dueas2023,
  author = {Dueñas, Maria Emilia and Peltier-Heap, Rachel E and Leveridge, Melanie and Annan, Roland S and Büttner, Frank H and Trost, Matthias},
  title = {Advances in high‐throughput mass spectrometry in drug discovery},
  journal = {EMBO Molecular Medicine},
  year = {2023},
  volume = {15},
  number = {1},
  doi = {10.15252/emmm.202114850}
}
Kostenlos starten →